PolarityTE Announces Howard Hechler from Smith & Nephew as the New Chief Business Officer
May 23 2018 - 8:30AM
PolarityTE, Inc. (Nasdaq:COOL) today announced the appointment of
Howard Hechler as Chief Business Officer. Mr. Hechler will lead the
Company’s M&A and partnering efforts, as well as work with
Executive Management to develop and execute the Company’s
commercialization strategy. He will also work to align pipeline
development efforts with the commercial strategy.
Mr. Hechler has nearly 15 years of life-sciences experience in
Pharma, Medical Devices, and Diagnostics. Most recently, he
was Senior Director of Corporate Development at Smith &
Nephew. Previously, he was Senior Director of Strategy and
Portfolio Development at Medtronic. Before that, he worked in
Commercial Strategy and M&A roles for various pharma,
incubator, and consulting firms, including Mallinckrodt, XL
TechGroup, and Campbell Alliance. Mr. Hechler has a B.A. from
Harvard University, as well as an MBA and Juris Doctorate, both
from the University of Virginia.
“We are excited to name Howard to this new role just as we
launch our first product and prepare for future pipeline
commercialization. We believe our partnering efforts are at a
critical inflection point, given our early successes with
PolarityTE and recent pipeline development advancements.
Howard’s industry knowledge, commercial strategy background, and
strong relationships in the M&A community will enable
PolarityTE to find the right partners at the right time as the
Company continues to roll out our platform technology,” said Denver
M. Lough, MD, PhD, Chairman and Chief Executive Officer of
PolarityTE.
Howard said, “I am very pleased to join PolarityTE, a company
that is committed to changing the face of regenerative
medicine. It is exciting to work in an environment where
there is so much opportunity to make a direct and substantial
impact on patient lives every day. I look forward to engaging with
the M&A community and leveraging my life-sciences background
and experience to further accelerate our commercial efforts and
find the best partners to work with us on this potentially
life-transforming technology.”
About PolarityTE™PolarityTE is
a commercial-stage biotechnology and regenerative biomaterials
company focused on transforming the lives of patients by
discovering, designing and developing a range of regenerative
tissue products and biomaterials for the fields of medicine,
biomedical engineering and material sciences. The PolarityTE
platform technology begins with a small piece of the patient’s own,
or autologous, healthy tissue, rather than artificially manipulated
individual cells. From this small piece of healthy autologous
tissue, the company creates an easily deployable, dynamic and
self-propagating product designed to enhance and stimulate the
patient’s own cells to regenerate the target tissues. Rather than
manufacturing with synthetic and foreign materials within
artificially engineered environments, PolarityTE manufactures with
the patient’s own tissue and uses the patient’s own body to support
the regenerative process to create the same tissue from which it
was derived. PolarityTE’s innovative method is intended to promote
and accelerate growth of the patient’s tissues to undergo a form of
effective regenerative healing.
Forward Looking
StatementsCertain statements contained in this release are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. They are generally
identified by words such as “believes,” “may,” “expects,”
“anticipates,” “intend,” “plan,” “will,” “would,” “should” and
similar expressions. Readers should not place undue reliance on
such forward-looking statements, which are based upon the Company’s
beliefs and assumptions as of the date of this release. The
Company’s actual results could differ materially due to risk
factors and other items described in more detail in the “Risk
Factors” section of the Company’s Annual Reports and other filings
with the SEC (copies of which may be obtained at www.sec.gov).
Subsequent events and developments may cause these forward-looking
statements to change. The Company specifically disclaims any
obligation or intention to update or revise these forward-looking
statements as a result of changed events or circumstances that
occur after the date of this release, except as required by
applicable law. Our actual results could differ materially due to
risk factors and other items described in more detail in the “Risk
Factors” section of the Company’s Annual Reports and other filings
with the SEC (copies of which may be obtained at www.sec.gov).
CONTACT
Investors:Rich
Haerleir@PolarityTE.com (385) 237-5786
Media:David SchullRusso
Partners LLCDavid.Schull@RussoPartnersLLC.com (858)
717-2310
Corner Growth Acquisition (NASDAQ:COOL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Corner Growth Acquisition (NASDAQ:COOL)
Historical Stock Chart
From Sep 2023 to Sep 2024